Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andrographolide plus Favipiravir vs Favipiravir Monotherapy in COVID-19
TCTR20210906002Phase 3Not yet recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of andrographolide, favipiravir in coronavirus disease 2019 (COVID-19), sponsored by Ratchadaphiseksomphot Endowment Fund. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
andrographolidefavipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210906002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210906002.